8 completed, 5 recruiting, 4 terminated, 3 not yet recruiting. 25 Phase 2, 4 Phase 1, 2 Phase 3.
Follow taxane: new trials by email Literature Review of taxane trials Research Report on taxane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy - Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 43 | 2026-11-01 | 2026-10-30 |
| Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer Paclitaxel, Cisplatin, Bioferon - Ovarian Cancer | Phase 2 | Not yet recruiting | Kalinski, Pawel, MD, PhD | 28 | 2026-10-01 | 2026-10-13 |
| Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer Fulvestaciclib, Trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 240 | 2026-10-01 | 2026-07-21 |
| Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer THP Regimen (Taxane + Trastuzumab + Pertuzumab), Trastuzumab Rezetecan (SHR-A1811) - HER2-positive Breast Cancer | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 124 | 2026-03-24 | 2026-06-15 |
| ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors ABL103, KEYTRUDA® (pembrolizumab), Taxane - Solid Tumors | Phase 1 / Phase 2 | Recruiting | ABL Bio, Inc. | 65 | 2025-08-06 | 2025-09-08 |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer Organoid-guided treatment, Taxane, Capecitabine - HER2-negative Breast Cancer, Advanced Breast Cancer | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 252 | 2024-10-01 | 2024-11-25 |
| Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer Quercetin, Dasatinib, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum - Triple-negative Breast Cancer | Phase 2 | Unknown | Fudan University | 10 | 2024-05-20 | 2024-07-08 |
| Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer Inosine, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum - Triple-negative Breast Cancer | Phase 2 | Completed | Fudan University | 10 | 2024-05-11 | 2025-07-18 |
| Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI - Breast Cancer, ER-positive Breast Cancer | Phase 2 | Active not recruiting | University of Miami | 24 | 2023-06-12 | 2026-01-13 |
| Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study Cisplatin, Computed Tomography, Gastrectomy - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 40 | 2023-04-20 | 2026-04-08 |
| A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer BMS-986442, Nivolumab, Docetaxel - Advanced Solid Tumors, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 36 | 2022-10-04 | 2025-03-18 |
| Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients Doxorubicin, Cyclophosphamide, Taxane - Early Breast Cancer | Phase 2 | Active not recruiting | Spanish Breast Cancer Research Group | 200 | 2020-10-02 | 2026-03-12 |
| Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer Induction Durvalumab, Chemotherapy, Radiation - Lung Cancer, Non-small Cell Carcinoma | Phase 2 | Terminated | Rachel Sanborn | 10 | 2020-06-18 | 2024-12-20 |
| Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) Surgery, carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin..., Niraparib - Ovarian Cancer Recurrent, Fallopian Tube Cancer | Phase 2 | Recruiting | Shanghai Gynecologic Oncology Group | 167 | 2019-10-18 | 2022-03-18 |
| Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) Paclitaxel, CB-839 - Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Completed | Calithera Biosciences, Inc | 52 | 2017-05-01 | 2022-09-28 |
| A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer Bavituximab, Taxane - Breast Cancer, Triple Negative Breast Neoplasms | Phase 2 | Withdrawn | Peregrine Pharmaceuticals | 2016-03-01 | 2017-03-09 | |
| Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer Bavituximab, Taxane - Metastatic Breast Cancer | Phase 2 / Phase 3 | Withdrawn | Peregrine Pharmaceuticals | 2015-12-01 | 2017-07-11 | |
| RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) RRx-001, Cisplatin, Etoposide - Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | EpicentRx, Inc. | 139 | 2015-06-01 | 2025-03-17 |
| A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Taxane, trastuzumab emtansine - Gastric Cancer | Phase 2 / Phase 3 | Terminated | Hoffmann-La Roche | 415 | 2012-09-03 | 2017-05-12 |
| Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) Paclitaxel, Docetaxel, Abraxane - Breast Neoplasms, Breast Cancer | Phase 2 | Completed | The Methodist Hospital Research Institute | 38 | 2011-09-01 | 2023-01-23 |
Showing 20 of 25. Sign in to see all of them.
Breast Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (5) · Triple Negative Breast Neoplasms (4) · Fallopian Tube Neoplasms (2) · Lung Neoplasms (2) · Ovarian Neoplasms (2) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Small Cell (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Neuroendocrine Tumors (1) · Stomach Neoplasms (1)
Bristol-Myers Squibb (3) · Fudan University (3) · Hoffmann-La Roche (2) · Peregrine Pharmaceuticals (2) · Shanghai Gynecologic Oncology Group (2) · ABL Bio, Inc. (1) · Bayer (1) · Calithera Biosciences, Inc (1) · EpicentRx, Inc. (1) · Guangdong Provincial People's Hospital (1) · Kalinski, Pawel, MD, PhD (1) · Mayo Clinic (1) · Rachel Sanborn (1) · Spanish Breast Cancer Research Group (1) · The First Affiliated Hospital of Soochow University (1)
United States (15) · China (8) · Canada (5) · Spain (5) · Italy (4) · Australia (3) · Belgium (3) · France (3) · Germany (3) · Poland (3) · United Kingdom (3) · Brazil (2) · Hungary (2) · Mexico (2) · Netherlands (2)
Bryan Oronsky, MD, PhD (1) · Charles J Nock, MD (1) · David Page, MD (1) · Frances Valdes-Albini, MD (1) · Jenny C Chang, MD (1) · Kathy Miller, MD (1) · Rachel Sanborn, MD (1) · Robert Edwards, MD (1) · Rongyu Zang, M.D., Ph.D. (1) · Rongyu Zang, MD,PhD (1) · Sam Whiting, MD, PhD (1) · Sangmi Lee (1)
PMID 24051172, PMID 28343975, PMID 30706247, PMID 31231122, PMID 31383985, PMID 32319233, PMID 33569311
2015 (1), 2019 (1)